Biosimilar Market Report

Global Biosimilar Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 24, 2022
  • PAGES：167
  • REPORT CODE：GMM772290
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilar market report explains the definition, types, applications, major countries, and major players of the Biosimilar market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Pfizer

    • BioXpress Therapeutics

    • BIOCAD

    • Reliance Life Sciences

    • Intas Pharmaceuticals Limited

    • Novartis

    • Boehringer Ingelheim

    • Coherus BioSciences

    • Celltrion

    • Dr Reddy’s Laboratories

    • Allergan plc

    • Genor BioPharma

    • Biocon

    By Type:

    • Human Growth Hormones

    • Monoclonal Antibodies

    • Insulin

    • Peptides

    • Erythropoietin

    • Others

    By End-User:

    • Oncology

    • Chronic and Autoimmune Diseases

    • Growth Hormone Deficiency

    • Infectious Diseases

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilar Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilar Outlook to 2028- Original Forecasts

    • 2.2 Biosimilar Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilar Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilar Market- Recent Developments

    • 6.1 Biosimilar Market News and Developments

    • 6.2 Biosimilar Market Deals Landscape

    7 Biosimilar Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilar Key Raw Materials

    • 7.2 Biosimilar Price Trend of Key Raw Materials

    • 7.3 Biosimilar Key Suppliers of Raw Materials

    • 7.4 Biosimilar Market Concentration Rate of Raw Materials

    • 7.5 Biosimilar Cost Structure Analysis

      • 7.5.1 Biosimilar Raw Materials Analysis

      • 7.5.2 Biosimilar Labor Cost Analysis

      • 7.5.3 Biosimilar Manufacturing Expenses Analysis

    8 Global Biosimilar Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilar Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilar Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilar Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilar Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Human Growth Hormones Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Insulin Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Peptides Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Erythropoietin Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilar Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Chronic and Autoimmune Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Growth Hormone Deficiency Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Infectious Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilar Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilar Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilar Consumption (2017-2022)

      • 10.2.2 Canada Biosimilar Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilar Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilar Consumption (2017-2022)

      • 10.3.2 UK Biosimilar Consumption (2017-2022)

      • 10.3.3 Spain Biosimilar Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilar Consumption (2017-2022)

      • 10.3.5 France Biosimilar Consumption (2017-2022)

      • 10.3.6 Italy Biosimilar Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilar Consumption (2017-2022)

      • 10.3.8 Finland Biosimilar Consumption (2017-2022)

      • 10.3.9 Norway Biosimilar Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilar Consumption (2017-2022)

      • 10.3.11 Poland Biosimilar Consumption (2017-2022)

      • 10.3.12 Russia Biosimilar Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilar Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilar Consumption (2017-2022)

      • 10.4.2 Japan Biosimilar Consumption (2017-2022)

      • 10.4.3 India Biosimilar Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilar Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilar Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilar Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilar Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilar Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilar Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilar Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilar Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilar Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilar Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilar Consumption (2017-2022)

      • 10.5.3 Chile Biosimilar Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilar Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilar Consumption (2017-2022)

      • 10.5.6 Peru Biosimilar Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilar Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilar Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilar Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilar Consumption (2017-2022)

      • 10.6.3 Oman Biosimilar Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilar Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilar Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilar Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilar Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilar Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilar Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilar Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilar Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilar Consumption (2017-2022)

    11 Global Biosimilar Competitive Analysis

    • 11.1 Pfizer

      • 11.1.1 Pfizer Company Details

      • 11.1.2 Pfizer Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Pfizer Biosimilar Main Business and Markets Served

      • 11.1.4 Pfizer Biosimilar Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 BioXpress Therapeutics

      • 11.2.1 BioXpress Therapeutics Company Details

      • 11.2.2 BioXpress Therapeutics Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 BioXpress Therapeutics Biosimilar Main Business and Markets Served

      • 11.2.4 BioXpress Therapeutics Biosimilar Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 BIOCAD

      • 11.3.1 BIOCAD Company Details

      • 11.3.2 BIOCAD Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 BIOCAD Biosimilar Main Business and Markets Served

      • 11.3.4 BIOCAD Biosimilar Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Reliance Life Sciences

      • 11.4.1 Reliance Life Sciences Company Details

      • 11.4.2 Reliance Life Sciences Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Reliance Life Sciences Biosimilar Main Business and Markets Served

      • 11.4.4 Reliance Life Sciences Biosimilar Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Intas Pharmaceuticals Limited

      • 11.5.1 Intas Pharmaceuticals Limited Company Details

      • 11.5.2 Intas Pharmaceuticals Limited Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Intas Pharmaceuticals Limited Biosimilar Main Business and Markets Served

      • 11.5.4 Intas Pharmaceuticals Limited Biosimilar Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Novartis

      • 11.6.1 Novartis Company Details

      • 11.6.2 Novartis Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Novartis Biosimilar Main Business and Markets Served

      • 11.6.4 Novartis Biosimilar Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Boehringer Ingelheim

      • 11.7.1 Boehringer Ingelheim Company Details

      • 11.7.2 Boehringer Ingelheim Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Boehringer Ingelheim Biosimilar Main Business and Markets Served

      • 11.7.4 Boehringer Ingelheim Biosimilar Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Coherus BioSciences

      • 11.8.1 Coherus BioSciences Company Details

      • 11.8.2 Coherus BioSciences Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Coherus BioSciences Biosimilar Main Business and Markets Served

      • 11.8.4 Coherus BioSciences Biosimilar Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Celltrion

      • 11.9.1 Celltrion Company Details

      • 11.9.2 Celltrion Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Celltrion Biosimilar Main Business and Markets Served

      • 11.9.4 Celltrion Biosimilar Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Dr Reddy’s Laboratories

      • 11.10.1 Dr Reddy’s Laboratories Company Details

      • 11.10.2 Dr Reddy’s Laboratories Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Dr Reddy’s Laboratories Biosimilar Main Business and Markets Served

      • 11.10.4 Dr Reddy’s Laboratories Biosimilar Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Allergan plc

      • 11.11.1 Allergan plc Company Details

      • 11.11.2 Allergan plc Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Allergan plc Biosimilar Main Business and Markets Served

      • 11.11.4 Allergan plc Biosimilar Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Genor BioPharma

      • 11.12.1 Genor BioPharma Company Details

      • 11.12.2 Genor BioPharma Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Genor BioPharma Biosimilar Main Business and Markets Served

      • 11.12.4 Genor BioPharma Biosimilar Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 Biocon

      • 11.13.1 Biocon Company Details

      • 11.13.2 Biocon Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 Biocon Biosimilar Main Business and Markets Served

      • 11.13.4 Biocon Biosimilar Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    12 Global Biosimilar Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilar Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Human Growth Hormones Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Insulin Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Peptides Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Erythropoietin Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilar Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Chronic and Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Growth Hormone Deficiency Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilar Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilar Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilar Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilar Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilar Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilar Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilar Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilar Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilar Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilar Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilar Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilar Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilar Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilar Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilar Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilar Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilar Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilar Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilar Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilar Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilar Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilar Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilar Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilar Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilar Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilar Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilar Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilar Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilar Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilar Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilar Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilar Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilar Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilar Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilar Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilar Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilar Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilar Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilar Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilar Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilar Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilar Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilar Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilar Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilar Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilar Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilar Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilar Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilar Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilar Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilar

    • Figure of Biosimilar Picture

    • Table Global Biosimilar Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilar Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Human Growth Hormones Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Insulin Consumption and Growth Rate (2017-2022)

    • Figure Global Peptides Consumption and Growth Rate (2017-2022)

    • Figure Global Erythropoietin Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Chronic and Autoimmune Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Growth Hormone Deficiency Consumption and Growth Rate (2017-2022)

    • Figure Global Infectious Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilar Consumption by Country (2017-2022)

    • Table North America Biosimilar Consumption by Country (2017-2022)

    • Figure United States Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilar Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilar Consumption by Country (2017-2022)

    • Figure Germany Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilar Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilar Consumption by Country (2017-2022)

    • Figure China Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilar Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilar Consumption by Country (2017-2022)

    • Figure Brazil Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilar Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilar Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilar Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilar Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilar Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilar Consumption by Country (2017-2022)

    • Figure Australia Biosimilar Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilar Consumption and Growth Rate (2017-2022)

    • Table Pfizer Company Details

    • Table Pfizer Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Biosimilar Main Business and Markets Served

    • Table Pfizer Biosimilar Product Portfolio

    • Table BioXpress Therapeutics Company Details

    • Table BioXpress Therapeutics Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioXpress Therapeutics Biosimilar Main Business and Markets Served

    • Table BioXpress Therapeutics Biosimilar Product Portfolio

    • Table BIOCAD Company Details

    • Table BIOCAD Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table BIOCAD Biosimilar Main Business and Markets Served

    • Table BIOCAD Biosimilar Product Portfolio

    • Table Reliance Life Sciences Company Details

    • Table Reliance Life Sciences Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Reliance Life Sciences Biosimilar Main Business and Markets Served

    • Table Reliance Life Sciences Biosimilar Product Portfolio

    • Table Intas Pharmaceuticals Limited Company Details

    • Table Intas Pharmaceuticals Limited Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intas Pharmaceuticals Limited Biosimilar Main Business and Markets Served

    • Table Intas Pharmaceuticals Limited Biosimilar Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Biosimilar Main Business and Markets Served

    • Table Novartis Biosimilar Product Portfolio

    • Table Boehringer Ingelheim Company Details

    • Table Boehringer Ingelheim Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Biosimilar Main Business and Markets Served

    • Table Boehringer Ingelheim Biosimilar Product Portfolio

    • Table Coherus BioSciences Company Details

    • Table Coherus BioSciences Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Coherus BioSciences Biosimilar Main Business and Markets Served

    • Table Coherus BioSciences Biosimilar Product Portfolio

    • Table Celltrion Company Details

    • Table Celltrion Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Biosimilar Main Business and Markets Served

    • Table Celltrion Biosimilar Product Portfolio

    • Table Dr Reddy’s Laboratories Company Details

    • Table Dr Reddy’s Laboratories Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy’s Laboratories Biosimilar Main Business and Markets Served

    • Table Dr Reddy’s Laboratories Biosimilar Product Portfolio

    • Table Allergan plc Company Details

    • Table Allergan plc Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan plc Biosimilar Main Business and Markets Served

    • Table Allergan plc Biosimilar Product Portfolio

    • Table Genor BioPharma Company Details

    • Table Genor BioPharma Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genor BioPharma Biosimilar Main Business and Markets Served

    • Table Genor BioPharma Biosimilar Product Portfolio

    • Table Biocon Company Details

    • Table Biocon Biosimilar Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Biosimilar Main Business and Markets Served

    • Table Biocon Biosimilar Product Portfolio

    • Figure Global Human Growth Hormones Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Peptides Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Erythropoietin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chronic and Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Growth Hormone Deficiency Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infectious Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilar Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilar Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilar Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilar Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US